Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab (KIA-ProRet)
|ClinicalTrials.gov Identifier: NCT00776763|
Recruitment Status : Completed
First Posted : October 21, 2008
Last Update Posted : July 22, 2011
Aims of the trial: Establishing the profile of the growth factors and other mediators of angiogenesis in different ocular fluids (aqueous humour, vitreous gel and ocular liquid in vitrectomized eyes), in the 2 most frequent proliferative retinopathies - diabetic proliferative retinopathy (PDR) and exudative age related macular degeneration (AMD). Following up the dynamic of this profile before and after intravitreal administration of Bevacizumab (Avastin) as an anti-VEGF blocker.
Materials: The research will be conducted on the following categories of patients groups:
- nondiabetic patients without AMD or any other diagnosed proliferative ocular disease (controls)
- patients with age related macular degeneration (AMD groups) before and after intravitreal injections with Avastin
- diabetic patients with different types of diabetic retinopathy, before and after intravitreal Avastin (diabetic groups) Methods: Samples from different ocular fluids will be collected from each group of patients. 10 growth factors and other 10 cytokines will be determined in the ocular fluids samples.
Results: The results from the biochemical measurements will be statistically interpreted in order to obtain conclusions for the clinical practice.
Conclusions: The conclusions of this trial will be used exclusively for research publications and communications, as well as for clinical practice.
|Condition or disease||Intervention/treatment||Phase|
|Proliferative Diabetic Retinopathy Age Related Macular Degeneration||Drug: Avastin intravitreal injection||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||The Profile of the Growth Factors and Other Mediators of Angiogenesis in the Ocular Fluids in Proliferative Retinopathies (AMD and PDR) Before and After the Intravitreal Administration of Bevacizumab (Avastin) as an Anti-VEGF Blocker|
|Study Start Date :||October 2008|
|Actual Primary Completion Date :||October 2009|
|Actual Study Completion Date :||December 2010|
Drug: Avastin intravitreal injection
1,25 mg of Bevacizumab (Avastin) will be intravitreally injected 4 weeks interval in the proliferative retinopathies groups (exudative age related macular degeneration and proliferative diabetic retinopathy)
- Growth Factors and Other Cytokines Measurements [ Time Frame: 1 month interval ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00776763
|Railway Universitary Hospital|
|Iasi, Romania, 700506|
|Principal Investigator:||NARCISA IANOPOL, Researcher||Railway Universitary Hospital|